{"entity":{"id":"nct07560111","kind":"trial","name":"A Phase II Study of GC101 in NSCLC","aka":[],"tldr":"A phase 2 trial of GC101 TIL in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Juncell Therapeutics, now recruiting.","summary":"A Phase II Study of GC101 in NSCLC is a phase 2 interventional study registered as NCT07560111 by Shanghai Juncell Therapeutics, with 28 participants planned, started 2026-06-01 and due to reach its primary completion in 2027-06-01. Interventions recorded: Autologous Tumor Infiltrating Lymphocytes. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07560111","url":"https://clinicaltrials.gov/study/NCT07560111"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["gc101-til"],"companies":["shanghai-juncell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07560111","phase":"2","setting":"An Open-Label, Phase II Study to Evaluate the Safety and Efficacy Using Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) in Patients With Non-Small Cell Lung Cancer","sponsor":"Shanghai Juncell Therapeutics","enrolled":28,"outcomes":[]},"route":"/trials/nct07560111/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"gc101-til","kind":"drug","name":"GC101 TIL","route":"/drugs/gc101-til/"}],"company":[{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","route":"/companies/shanghai-juncell-therapeutics/"}]}}